Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nichi-Iko Manufacturing Plant Raided Over Illegal Production – Report

Raid Follows Earlier Suspension Of Sales And Production

Executive Summary

Japanese generics giant Nichi-Iko had a key manufacturing plant raided by Japanese authorities and regulator the PMDA, per media reports, following the recent suspension of production and sales at the site in the Toyama prefecture.

You may also be interested in...



Nichi-Iko Set To Delist In March As Tamura Steps Down As CEO

After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.

Earnings Recovery For Nichi-Iko Unlikely Before Full Resumption Of Toyama Shipments

Nichi-Iko still has a long road to recovery ahead as it attempts to get its Toyama plant back on its feet.

Nichi-Iko Pledges Return To Form After Turbulent Financial Year

Nichi-Iko experienced substantial losses over the financial year ended 31 March 2022, as one of many Japanese generics firms found to have been falling short on GMP since the beginning of 2021.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel